MPI Research was founded in 1962. MPI Research helps drug developers answer a crucial question: Is it safe? The contract research organization (CRO) specializes in providing pre-clinical research services to pharmaceutical, medical device, chemical, and agricultural development companies, as well as regulatory and other government agencies. Its toxicology testing services investigate and determine the safety and dosage levels of substances being considered for use in drugs, pesticides, petrochemicals, and food additives. MPI Research also offers contract bioanalytical and pharmacology services.

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

Novartis Pharmaceuticals holds down the fort on this side of the big pond. As the US pharmaceuticals marketing affiliate of Swiss drug giant Novartis AG, the company helps with the development and sales of its parent company's products in the US. Its product line addresses a range of ailments including cardiovascular and respiratory diseases, gastrointestinal complaints, central nervous system disorders, cancer and blood disorders, bone and joint conditions, and organ transplants. Key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin.

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Aspen Pharmacare Holdings is the holding company of Aspen Pharmacare. The company is Africa's largest generic pharmaceutical manufacturer and a major supplier of branded pharmaceutical and healthcare products to southern African and some other international markets. Its products include pain medication, vitamins, cough and cold medicines, laxatives, medicine for indigestion, and aids to help people quit smoking and lose weight. Aspen Pharmacare also led the way in developing the first anti-retroviral medication in South Africa for AIDS treatment. Aspen Pharmacare Holdings Ltd. company has manufacturing facilities in Africa, India, and Latin America.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.